TY  - JOUR
AU  - Óváry, Csaba
AU  - Bereczki, Csaba
AU  - Gődény, Mária
AU  - Battyáni, István
AU  - Kovács, Péter
AU  - Fogarasi, András
AU  - Janszky, József
AU  - Juhos, Vera
AU  - Rosdy, Beáta
AU  - Hollódy, Katalin
AU  - Bessenyei, Mónika
AU  - Barsi, Péter
AU  - Martos, János
AU  - Békés, Judit
AU  - Borbély, Katalin
TI  - A Belügyminisztérium egészségügyi szakmai irányelve az epilepsziás rohamok és epilepszia felismeréséről, kezeléséről és az epilepsziás betegek gondozásáról
JF  - EGÉSZSÉGÜGYI KÖZLÖNY
J2  - EGÉSZSÉGÜGYI KÖZLÖNY
VL  - 74
PY  - 2024
IS  - 7
SP  - 1256
EP  - 1310
PG  - 55
SN  - 2063-1146
UR  - https://m2.mtmt.hu/api/publication/34833014
ID  - 34833014
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Kovács, Péter
AU  - Németh, Attila
AU  - Gonda, Xénia
AU  - Csigó, Katalin
AU  - Purebl, György
AU  - Kiss, Dániel Balázs
AU  - Ozvald, Gabriella
TI  - A Belügyminisztérium egészségügyi szakmai irányelve a pszichoterápiás ellátásról
JF  - EGÉSZSÉGÜGYI KÖZLÖNY
J2  - EGÉSZSÉGÜGYI KÖZLÖNY
VL  - 74
PY  - 2024
IS  - 6
SP  - 909
EP  - 1043
PG  - 135
SN  - 2063-1146
UR  - https://m2.mtmt.hu/api/publication/34832954
ID  - 34832954
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Suba, Zsuzsanna
TI  - DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care.
JF  - CANCERS
J2  - CANCERS
VL  - 16
PY  - 2024
IS  - 8
SN  - 2072-6694
DO  - 10.3390/cancers16081573
UR  - https://m2.mtmt.hu/api/publication/34827151
ID  - 34827151
N1  - Journal Article; Review
AB  - In tumors, somatic mutagenesis presumably drives the DNA damage response (DDR) via altered regulatory pathways, increasing genomic instability and proliferative activity. These considerations led to the standard therapeutic strategy against cancer: the disruption of mutation-activated DNA repair pathways of tumors.Justifying that cancer cells are not enemies to be killed, but rather that they are ill human cells which have the remnants of physiologic regulatory pathways.1. Genomic instability and cancer development may be originated from a flaw in estrogen signaling rather than excessive estrogen signaling; 2. Healthy cells with genomic instability exhibit somatic mutations, helping DNA restitution; 3. Somatic mutations in tumor cells aim for the restoration of DNA damage, rather than further genomic derangement; 4. In tumors, estrogen signaling drives the pathways of DNA stabilization, leading to apoptotic death; 5. In peritumoral cellular infiltration, the genomic damage of the tumor induces inflammatory cytokine secretion and increased estrogen synthesis. In the inflammatory cells, an increased growth factor receptor (GFR) signaling confers the unliganded activation of estrogen receptors (ERs); 6. In breast cancer cells responsive to genotoxic therapy, constitutive mutations help the upregulation of estrogen signaling and consequential apoptosis. In breast tumors non-responsive to genotoxic therapy, the possibilities for ER activation via either liganded or unliganded pathways are exhausted, leading to farther genomic instability and unrestrained proliferation.Understanding the real character and behavior of human tumors at the molecular level suggests that we should learn the genome repairing methods of tumors and follow them by supportive therapy, rather than provoking additional genomic damages.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Ludwig, Gerd
AU  - Randelovic, Ivan
AU  - Dimić, Dušan
AU  - Komazec, Teodora
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Rüffer, Tobias
AU  - Kaluđerović, Goran N
TI  - (Pentamethylcyclopentadienyl)chloridoiridium(III) Complex Bearing Bidentate Ph2PCH2CH2SPh-κP,κS Ligand.
JF  - BIOMOLECULES
J2  - BIOMOLECULES
VL  - 14
PY  - 2024
IS  - 4
SN  - 2218-273X
DO  - 10.3390/biom14040420
UR  - https://m2.mtmt.hu/api/publication/34827138
ID  - 34827138
N1  - Journal Article; Research Support, Non-U.S. Gov't
AB  - The (pentamethylcyclopentadienyl)chloridoiridium(III) complex bearing a κP,κS-bonded Ph2PCH2CH2SPh ligand ([Ir(η5-C5Me5)Cl(Ph2P(CH2)2SPh-κP,κS)]PF6, (1)] was synthesized and characterized. Multinuclear (1H, 13C and 31P) NMR spectroscopy was employed for the determination of the structure. Moreover, SC-XRD confirmed the proposed structure belongs to the "piano stool" type. The Hirshfeld surface analysis outlined the most important intermolecular interactions in the structure. The crystallographic structure was optimized at the B3LYP-D3BJ/6-311++G(d,p)(H,C,P,S,Cl)/LanL2DZ(Ir) level of theory. The applicability of this level was verified through a comparison of experimental and theoretical bond lengths and angles, and 1H and 13C NMR chemical shifts. The Natural Bond Orbital theory was used to identify and quantify the intramolecular stabilization interactions, especially those between donor atoms and Ir(III) ions. Complex 1 was tested on antitumor activity against five human tumor cell lines: MCF-7 breast adenocarcinoma, SW480 colon adenocarcinoma, 518A2 melanoma, 8505C human thyroid carcinoma and A253 submandibular carcinoma. Complex 1 showed superior antitumor activity against cisplatin-resistant MCF-7, SW480 and 8505C cell lines. The mechanism of tumoricidal action on 8505C cells indicates the involvement of caspase-induced apoptosis, accompanied by a considerable reduction in ROS/RNS and proliferation potential of treated cells.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Wheatley, Duncan A
AU  - Berardi, Rossana
AU  - Climent Duran, Miguel A
AU  - Tomiak, Anna
AU  - Greystoke, Alastair P
AU  - Joshua, Anthony M
AU  - Arkenau, Hendrik-Tobias
AU  - Géczi, Lajos
AU  - Garcia-Corbacho, Javier
AU  - Paz-Ares, Luis G
AU  - Hussain, Syed A
AU  - Petruželka, Lubos
AU  - Delmonte, Angelo
AU  - Chappey, Colombe
AU  - Masters, Joanna C
AU  - Michelon, Elisabete
AU  - Murphy, Danielle A
AU  - Mwewa, Sandrine
AU  - Cesari, Rossano
AU  - Doger de Speville, Bernard
TI  - First-line avelumab plus chemotherapy in patients with advanced solid tumors. results from the phase 1b/2 JAVELIN Chemotherapy Medley study.
TS  - results from the phase 1b/2 JAVELIN Chemotherapy Medley study.
JF  - Cancer Research Communications
VL  - Apr 26
PY  - 2024
SN  - 2767-9764
DO  - 10.1158/2767-9764.CRC-23-0459
UR  - https://m2.mtmt.hu/api/publication/34827132
ID  - 34827132
AB  - Chemotherapy can potentially enhance the activity of immune checkpoint inhibitors by promoting immune priming. The phase 1b/2 JAVELIN Chemotherapy Medley trial evaluated first-line avelumab + concurrent chemotherapy in patients with advanced urothelial carcinoma or nonsmall cell lung cancer (NSCLC).Avelumab 800 mg or 1200 mg was administered continuously every 3 weeks (Q3W) with standard doses of cisplatin + gemcitabine in patients with urothelial carcinoma, or carboplatin + pemetrexed in patients with nonsquamous NSCLC. Dual primary endpoints were dose-limiting toxicity (DLT; phase 1b) and confirmed objective response (phase 1b/2).In phase 1b, urothelial carcinoma and NSCLC cohorts received avelumab 800 mg (n=13 and n=6, respectively) or 1200 mg (n=6 each) + chemotherapy. In evaluable patients with urothelial carcinoma treated with avelumab 800 mg or 1200 mg + chemotherapy, DLT occurred in 1/12 (8.3%) and 1/6 (16.7%), respectively; no DLT occurred in the NSCLC cohort. In phase 2, 35 additional patients with urothelial carcinoma received avelumab 1200 mg + chemotherapy. Across all treated patients, safety profiles were similar irrespective of avelumab dose. Objective response rates (95% confidence internal) with avelumab 800 mg or 1200 mg + chemotherapy, respectively, across phase 1b/2, were 53.8% (25.1-80.8) and 39.0% (24.2-55.5) in urothelial carcinoma, and 50.0% (11.8-88.2) and 33.3% (4.3-77.7) in NSCLC.Preliminary efficacy and safety findings with avelumab + chemotherapy in urothelial carcinoma and NSCLC were consistent with previous studies of similar combination regimens. Conclusions about clinical activity are limited by small patient numbers.gov identifier, NCT03317496.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Wéber, András
AU  - Vignat, Jerome
AU  - Shah, Richa
AU  - Morgan, Eileen
AU  - Laversanne, Mathieu
AU  - Nagy, Péter
AU  - Kenessey, István
AU  - Znaor, Ariana
TI  - Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates.
JF  - WORLD JOURNAL OF UROLOGY
J2  - WORLD J UROL
VL  - 42
PY  - 2024
IS  - 1
PG  - 10
SN  - 0724-4983
DO  - 10.1007/s00345-024-04949-8
UR  - https://m2.mtmt.hu/api/publication/34805400
ID  - 34805400
AB  - In 2020, bladder cancer (BC) was the seventh most prevalent cancer in the world, with 5-year prevalence of more than 1.7 million cases. Due to the main risk factors-smoking and chemical exposures-associated with BC, it is considered a largely preventable and avoidable cancer. An overview of BC mortality can allow an insight not only into the prevalence of global risk factors, but also into the varying efficiency of healthcare systems worldwide. For this purpose, this study analyzes the national mortality estimates for 2020 and projected future trends up to 2040.Age-standardized mortality rates per 100,000 person-years of BC for 185 countries by sex were obtained from the GLOBOCAN 2020 database, operated by the International Agency for Research on Cancer (IARC). Mortality rates were stratified according to sex and Human Development Index (HDI). BC deaths were projected up to 2040 on the basis of demographic changes, alongside different scenarios of annually increasing, stable or decreasing mortality rates from the baseline year of 2020.In 2020, nearly three times more men died from BC than women, with more than 210,000 deaths in both sexes combined, worldwide. Regardless of gender, more than half of the total BC deaths were from countries with a very high HDI. According to our projections, while the number of deaths for men can only increase up to 54% (from 159 to around 163-245 thousand), for women it is projected to increase two- to three-fold (from 50 to around 119-176 thousand) by 2040. The burden of BC mortality in countries with a very high HDI versus high HDI appears to converge by 2040 for both sexes.Opposite mortality trends by gender highlight the urgent need for immediate interventions to expand anti-tobacco strategies, especially for women. The implementation of more strict occupational health and safety regulations could also prevent exposures associated with BC. Improving the ability to detect BC earlier and access to treatment can have a significant positive impact on reducing mortality rates, minimizing economic costs, and enhancing the quality of life for patients.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Massari, Francesco
AU  - Santoni, Matteo
AU  - Takeshita, Hideki
AU  - Okada, Yohei
AU  - Tapia, Jose Carlos
AU  - Basso, Umberto
AU  - Maruzzo, Marco
AU  - Scagliarini, Sarah
AU  - Büttner, Thomas
AU  - Fornarini, Giuseppe
AU  - Myint, Zin W
AU  - Galli, Luca
AU  - Souza, Vinicius Carrera
AU  - Pichler, Renate
AU  - De Giorgi, Ugo
AU  - Gandur, Nathalia
AU  - Lam, Elaine T
AU  - Gilbert, Danielle
AU  - Popovic, Lazar
AU  - Grande, Enrique
AU  - Mammone, Giulia
AU  - Berardi, Rossana
AU  - Crabb, Simon J
AU  - Kemp, Robert
AU  - Molina-Cerrillo, Javier
AU  - Freitas, Marcelo
AU  - Luz, Murilo
AU  - Iacovelli, Roberto
AU  - Calabrò, Fabio
AU  - Tural, Deniz
AU  - Atzori, Francesco
AU  - Küronya, Zsófia
AU  - Chiari, Rita
AU  - Campos, Saul
AU  - Caffo, Orazio
AU  - Fay, André P
AU  - Kucharz, Jakub
AU  - Zucali, Paolo Andrea
AU  - Rinck, José Augusto
AU  - Zeppellini, Annalisa
AU  - Bastos, Diogo Assed
AU  - Aurilio, Gaetano
AU  - Mota, Augusto
AU  - Trindade, Karine
AU  - Ortega, Cinzia
AU  - Sade, Juan Pablo
AU  - Rizzo, Mimma
AU  - Fiala, Ondřej
AU  - Vau, Nuno
AU  - Giannatempo, Patrizia
AU  - Barillas, Allan
AU  - Monteiro, Fernando Sabino M
AU  - Dauster, Breno
AU  - Mennitto, Alessia
AU  - Nogueira, Lucas
AU  - de Carvalho Fernandes, Roni
AU  - Seront, Emmanuel
AU  - Aceituno, Luís Garcia
AU  - Grillone, Francesco
AU  - Cutuli, Hernan Javier
AU  - Fernandez, Mauricio
AU  - Bassanelli, Maria
AU  - Kopp, Ray Manneh
AU  - Roviello, Giandomenico
AU  - Abahssain, Halima
AU  - Procopio, Giuseppe
AU  - Milella, Michele
AU  - Kopecky, Jindrich
AU  - Martignetti, Angelo
AU  - Messina, Carlo
AU  - Caitano, Manuel
AU  - Inman, Eva
AU  - Kanesvaran, Ravindran
AU  - Herchhorn, Daniel
AU  - Santini, Daniele
AU  - Bamias, Aristotelis
AU  - Bisonni, Renato
AU  - Mosca, Alessandra
AU  - Morelli, Franco
AU  - Maluf, Fernando
AU  - Soares, Andrey
AU  - Nunes, Fernando
AU  - Pinto, Alvaro
AU  - Zgura, Anca
AU  - Incorvaia, Lorena
AU  - Ansari, Jawaher
AU  - Zabalza, Ignacio Ortego
AU  - Landmesser, Johannes
AU  - Rizzo, Alessandro
AU  - Mollica, Veronica
AU  - Marchetti, Andrea
AU  - Rosellini, Matteo
AU  - Sorgentoni, Giulia
AU  - Battelli, Nicola
AU  - Buti, Sebastiano
AU  - Porta, Camillo
AU  - Bellmunt, Joaquim
TI  - Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy. the ARON-2 study.
TS  - the ARON-2 study.
JF  - CANCER IMMUNOLOGY IMMUNOTHERAPY
J2  - CANCER IMMUNOL IMMUN
VL  - 73
PY  - 2024
IS  - 6
SP  - 106
SN  - 1432-0851
DO  - 10.1007/s00262-024-03682-w
UR  - https://m2.mtmt.hu/api/publication/34805365
ID  - 34805365
AB  - Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy.Medical records of patients with documented metastatic UC treated by pembrolizumab as second-line therapy were retrospectively collected from 88 institutions in 23 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS) and overall response rate (ORR). Cox proportional hazards models were adopted to explore the presence of prognostic factors.In total, 836 patients were included: 544 patients (65%) received pembrolizumab after progression to first-line platinum-based chemotherapy in the metastatic setting (cohort A) and 292 (35%) after recurring within < 12 months since the completion of adjuvant or neoadjuvant chemotherapy (cohort B). The median follow-up time was 15.3 months. The median OS and the ORR were 10.5 months and 31% in the overall study population, 9.1 months and 29% in cohort A and 14.6 months and 37% in cohort B. At multivariate analysis, ECOG-PS ≥ 2, bone metastases, liver metastases and pembrolizumab setting (cohort A vs B) proved to be significantly associated with worst OS and PFS. Stratified by the presence of 0, 1-2 or 3-4 prognostic factors, the median OS was 29.4, 12.5 and 4.1 months (p < 0.001), while the median PFS was 12.2, 6.4 and 2.8 months, respectively (p < 0.001).Our study confirms that pembrolizumab is effective in the advanced UC real-world context, showing outcome differences between patients recurred or progressed after platinum-based chemotherapy.
LA  - English
DB  - MTMT
ER  - 

TY  - GEN
AU  - Jánváry, Zsolt Levente
TI  - Célzott sugárkezelés és sugársebészet
PY  - 2024
UR  - https://m2.mtmt.hu/api/publication/34795787
ID  - 34795787
N1  - Előadás
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - GEN
AU  - Bíró, Krisztina
TI  - Urológiai daganatok gyógyszeres kezelése
PY  - 2024
UR  - https://m2.mtmt.hu/api/publication/34795710
ID  - 34795710
N1  - Előadás
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - GEN
AU  - Gesztesi, László
TI  - Urológiai daganatok sugárkezelése
PY  - 2024
UR  - https://m2.mtmt.hu/api/publication/34795682
ID  - 34795682
N1  - Előadás
LA  - Hungarian
DB  - MTMT
ER  -